9980/3	Refractory anemia
		del(7)(p11-15) solely
		dup (11q) in myeloid malignancies
		i(X)(p10) in female patients
		Refractory anemia (RA)
		Refractory anemia without sideroblasts
	9982/3	Refractory anemia with sideroblasts
		i(X)(p10) in female patients
		Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
		Refractory anemia with ringed sideroblasts (RARS)
		t(1;3)(p36;q21) RPN1/PRDM16
		Refractory anemia with ringed sideroblasts
		RARS
		Refractory anemia with ring sideroblasts associated with marked thrombocytosis
	9983/3	Refractory anemia with excess blasts
		del(7)(p11-15) solely
		dup (11q) in myeloid malignancies
		dup(1)(q11-q44) in myeloid malignancies
		i(4p) in myeloid malignancies
		inv(11)(p15q23) NUP98/KMT2A
		i(X)(p10) in female patients
		Myelodysplastic syndrome with excess blasts
		r(8)
		Refractory anemia with excess blasts (RAEB) in 2003
		t(1;3)(p36;q21) RPN1/PRDM16
		t(2;11)(p21;q23) without KMT2A (MLL) rearrangement
		RAEB
		RAEB I
		RAEB II
	9984/3	Refractory anemia with excess blasts in transformation [obs]
		RAEB-T
	9985/3	Refractory cytopenia with multilineage dysplasia
		dup(1)(q11-q44) in myeloid malignancies
		Refractory cytopenia of childhood
	9986/3	Myelodysplastic syndrome with 5q deletion (5q-) syndrome
		del (5q) solely in Myelodysplastic syndrome
		Myelodysplastic syndrome with isolated del (5q)
	9987/3	Therapy-related myelodysplastic syndrome, NOS
		Therapy-related myelodysplastic syndrome, alkylating agent related
		Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related
	9989/3	Myelodysplastic syndrome, NOS
		Atypical Chronic Myeloid Leukemia (aCML)
		Childhood myelodysplastic syndromes
		Classification of myelodysplastic syndromes 2015
		Classification of myelodysplasic syndromes 1999
		Chronic Myelomonocytic Leukemia (CMML)
		del(13q) in myeloid malignancies
		del (13q)
		del(17p) in myeloid malignancies
		del(1p) solely
		del(20q) in myeloid malignancies
		del(21)(q21q22) USP16/RUNX1
		del(5q) in myeloid neoplasms
		del(6q)
		-7/del(7q) in childhood
		-7/del(7q) in adults
		del(9q) solely
		der(9)t(1;9)(q11-12;q34)
		Unbalanced whole-arm translocation der(1;10)(q10-q11;p10-p12)
		Unbalanced whole-arm translocation der(1;13) in hematologic malignancies
		dic(1;15)(p11;p11)
		dic(5;17)(q11-14;p11-13)
		dic(17;20)(p11.2;q11.2)
		dup(1)(q11-q44) in myeloid malignancies
		i(17q) solely in myeloid malignancies
		i(5)(p10) in acute myeloid leukemia
		i(7)(q10)
		ider(20q) in Myeloid Malignancies
		idic(X)(q13)
		inv(6)(p15q13)
		inv(6)(p25q13)
		inv(11)(p15q22) NUP98/DDX10::t(11;11)(p15;q22) NUP98/DDX10
		inv(11)(p15q23) NUP98/KMT2A
		inv(11)(q21q23) KMT2A/MAML2 in therapy related leukemias
		inv(12)(p13q15) ETV6/PTPRR
		inv(16)(p13q22) CBFB/MYH11::t(16;16)(p13;q22) CBFB/MYH11::del(16)(q22) CBFB/MYH11
		inv(18)(p11q21)
		inv(3)(q21q26) RPN1/MECOM::t(3;3)(q21;q26) RPN1/MECOM::ins(3;3)(q26;q21q26) RPN1/MECOM
		inv(3)(p24q26) ?/MECOM
		i(X)(p10) in female patients
		i(Xq10) in female patients
		MLL amplification in leukemia
		-21 or monosomy 21 (solely)
		Monosomal karyotype (MK) in myeloid malignancies
		Myelodysplastic syndrome with excess blasts
		+X solely in myeloid malignancies
		Refractory anemia with excess blasts (RAEB) in 2003
		Refractory anemia (RA)
		Refractory anemia with ringed sideroblasts (RARS)
		der(1)t(1;1)(p36;q11-q32) in hematopoietic malignancies
		t(1;2)(p36;p21) THADA/PRDM16
		t(1;3)(p36;q21) PSMD2/PRDM16 ???
		t(1;3)(p36;p21)
		t(1;3)(p36;q21) RPN1/PRDM16
		t(1;6)(p36;p21)
		der(1;7)(q10;p10)
		t(1;11)(p32;q23) KMT2A/EPS15
		der(11)t(1;11)(q11-23;q14-25)
		t(1;12)(p36;p13) ETV6/MDS2
		t(1;12)(q21;p13) ETV6/ARNT
		der(12)t(1;12)(q11-21;p11-13)
		t(1;12)(q21;q24)
		der(1;14)(p10 or q10;p10 or q10)
		t(1;16)(q11;q11)
		t(1;18)(q10;q10)
		t(1;19)(p13;p13.1)
		der(20)t(1;20)(q10-21;q11-13)
		t(1;21)(p36;q22) RUNX1/PRDM16
		t(2;3)(p15-23;q26-27) ?/MECOM
		t(2;4)(p23;q25-q35)
		t(2;8)(q12;p11) RANBP2/FGFR1
		t(2;11)(p21;q23) KMT2A/?
		t(2;11)(p21;q23) without KMT2A (MLL) rearrangement
		t(2;11)(q31;p15) NUP98/HOXD13::t(2;11)(q31;p15) NUP98/HOXD11
		t(2;12)(q31;p13) ETV6/?
		t(3;3)(p24;q26) ?/MECOM
		t(3;4)(p21;q34)
		t(3;5)(q25;q34) NPM1/MLF1
		t(3;5)(q21;q31)
		t(3;7)(q26;q21) CDK6/MECOM
		t(3;8)(q26;q24) PVT1/MECOM
		t(3;11)(p25;p15) ANKRD28/NUP98
		t(3;11)(q12;p15) NUP98/LNP1
		t(3;12)(q26;p13) ETV6/MECOM::t(3;12)(q26;p13) ETV6/EVI1
		t(3;16)(q21;q22)
		t(3;18)(q26;q11) ?/MECOM
		t(3;21)(q26;q22) RUNX1/MECOM
		t(3;21)(q26;q11) NRIP1/MECOM
		t(4;5)(q31;q31)
		t(4;11)(p12;q23) KMT2A/FRYL
		t(5;11)(q31;q23) KMT2A/ARHGAP26
		t(5;12)(q33;p13) ETV6/PDGFRB
		t(5;12)(q13;p13) ?/ETV6
		t(5;12)(q31;p13) ETV6/ACSL6 in MDS,AML and AEL
		t(5;16)(q32;p13) NDE1/PDGFRB
		t(5;17)(q33;p11.2) SPECC1/PDGFRB
		t(5;17)(q33;p13) RABEP1/PDGFRB
		t(5;17)(q35;q21) without RARA involvement in non-M3 AML
		t(5;21)(q13;q22) RUNX1/?
		t(5;7)(q33;q11) HIP1/PDGFRB
		t(6;9)(p22;q34) DEK/NUP214
		t(6;9)(p22;q34) DEK/NUP214 in Childhood
		t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
		t(6;20)(q13;q12) LMBRD1/CHD6
		t(6;21)(p22;q22) RUNX1-?
		t(7;12)(p12;q13) HMGA2 truncated
		t(8;9)(p22;p24) PCM1/JAK2
		t(8;12)(q12;p13)
		t(8;12)(q22;q13) HMGA2/?
		t(8;21)(q23;q22) RUNX1/ZFPM2
		t(9;12)(q22;p12) ETV6/SYK
		t(X;20)(q13;q13.3)
		t(10;12)(q24;p13) ETV6/GOT1
		t(10;16)(q22;p13) KAT6B/CREBBP
		t(11;14)(p15;q22) AP2A2/NID2
		t(11;16)(q23;p13.3) KMT2A/CREBBP
		t(11;17)(q23;q25) KMT2A/SEPT9
		t(11;17)(p15;q21) NUP98/?
		t(11;20)(p15;q11) NUP98/TOP1
		t(11;21)(q13;q22) RUNX1/MACROD1
		t(11;22)(q13;q13) HRASLS5/PHF21B
		der(18)t(1;18)(q10-25;q11-23)
		t(12;12)(p13;q13) HMGA2/?
		t(12;12)(p13;q13) ETV6/BAZ2A
		t(12;13)(p12;q12-14) ETV6/CDX2
		t(12;13)(p13;q14) LIN00598/ETV6
		t(12;14)(q13;q31) HMGA2/?
		t(12;17)(p13;p13) ETV6/PER1
		t(12;18)(p13;q12) ETV6/SETBP1
		t(12;19)(p13;p13) TCF3/ZNF384
		t(12;20)(q15;q11.2) HMGA2 truncated
		t(12;22)(p13;q12) MN1/ETV6
		t(14;21)(q22;q22) RUNX1/?
		t(15;21)(q22;q22) RUNX1/?
		t(16;21)(q24;q22) RUNX1/CBFA2T3
		t(20;21)(q13;q22) RUNX1/?
		t(20;21)(q13.2;q22.12) ZFP64/RUNX1
		t(6;8)(q27;p12) FGFR1OP/FGFR1
		t(8;13)(p11;q12) ZMYM2/FGFR1
		t(9;12)(q34;p13) ETV6/ABL1
		Isolated tetrasomy 8 in AML, MDS and MPD
		+11 or trisomy 11 (solely) KMT2A
		+13 or trisomy 13
		+14 or trisomy 14 (solely)
		+15 or trisomy 15 (as sole autosomal abnormality)
		+16 or trisomy 16 (solely)
		+18 or trisomy 18 in lymphoproliferative disorders
		+19 or trisomy 19
		+20 or trisomy 20 (solely)
		+21 or trisomy 21
		+2 or trisomy 2
		+6 or trisomy 6
		+7 or trisomy 7 (solely)
		+8 or trisomy 8
		+9 or trisomy 9
		1q triplication in hematologic malignancies
		t(Y;1)(q12;q12)
		1q translocations (unbalanced) in myeloid malignancies
		Y loss in leukemia
		3q26 rearrangements (MECOM) in myeloid malignancies
		11q23 rearrangements (KMT2A) in leukaemia
		12p abnormalities in myeloid malignancies
		t(9;12)(p24;p13) ETV6/JAK2
		Infant leukaemias::Congenital leukaemias::Neonatal leukaemias
		Preleukaemia [obs]
		Preleukemic syndrome [obs]
		Myelodysplastic syndrome, unclassifiable